Evidence reviews – March 2024
The following documents contain the evidence that was used to develop the 2024 recommendations:
- Information and support
- Support interventions
- Configuration of services
- Optimal methods of assessing the probability of having a pathogenic variant
- Optimal methods of assessing the absolute risk of having a pathogenic variant
- Carrier probability – any person
- Carrier probability – family history of a syndrome
- Populations with high prevalence
- Carrier probability – people with ovarian cancer
- Which genes to include in gene panel testing
- Benefits and risks of surveillance
- Methods of surveillance
- Preventive medicines
- Risk-reducing surgery
- Pathology protocol
- Hormone replacement therapy after risk-reducing surgery
Other supporting evidence
This page was last updated: